×
About 3,813 results

ALLMedicine™ Biosimilars Center

Research & Reviews  936 results

Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, E...
https://doi.org/10.1080/07357907.2022.2093895
Cancer Investigation; Papautsky EL, Carlson M et. al.

Jul 1st, 2022 - Despite the incorporation of trastuzumab biosimilars (to treat HER2-positive breast cancer) in clinical practice guidelines, gaps remain such as patient and clinician education. We hosted a webinar comprised of a panel of biosimilars experts, onco...

Comparative efficacy trials in inflammatory bowel disease: current and future implicati...
https://doi.org/10.1097/MOG.0000000000000854 10.1016/j.cgh.2021.07.038
Current Opinion in Gastroenterology; Ahuja D, Singh S

Jun 29th, 2022 - Over the last decade, there has been rapid expansion of the therapeutic armamentarium, and evolution of treatment strategies, for the management of inflammatory bowel diseases (IBDs). Consequently, there is an increasing need for head-to-head or c...

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): update...
https://doi.org/10.1038/s41584-022-00798-0 10.1136/ard.2008.094946 10.1136/bmj.39489.470347.AD 10.1136/bmj.d5928 10.3899/jrheum.200126 10.3899/jrheum.150614 10.1002/art.40851 10.1136/annrheumdis-2019-216500 10.1136/annrheumdis-2018-214746 10.1016/S0140-6736(20)30564-X 10.1136/annrheumdis-2019-215386 10.1056/NEJMoa2022516 10.1016/j.semarthrit.2018.05.011 10.1136/annrheumdis-2016-210322 10.1016/S0140-6736(19)32534-6 10.1016/S0140-6736(18)32463-2 10.1136/annrheumdis-2020-219601 10.1136/annrheumdis-2020-218808 10.1002/art.40728 10.1056/NEJMoa1412679 10.3899/jrheum.160275 10.1186/s13075-019-1831-0 10.1136/annrheumdis-2019-216835 10.1016/S0140-6736(20)30263-4 10.1136/annrheumdis-2021-eular.2678 10.1136/annrheumdis-2016-210724 10.1136/annrheumdis-2020-218870 10.1080/00365521.2018.1518482 10.1097/MD.0000000000005652 10.3109/08820538.2016.1170161 10.1007/s10067-014-2746-4 10.1038/s41572-021-00293-y 10.1002/acr.24820 10.3899/jrheum.170150 10.3899/jrheum.200127 10.1016/S0140-6736(15)00347-5 10.1038/s41584-019-0175-0 10.1136/annrheumdis-2021-220865 10.1136/annrheumdis-2021-219961 10.1038/s41584-019-0285-8 10.1002/art.41191 10.3899/jrheum.161459 10.3899/jrheum.111245
Nature Reviews. Rheumatology; Coates LC, Soriano ER et. al.

Jun 28th, 2022 - Since the second version of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015, therapeutic options for psoriatic arthritis (PsA) have advanced considerably. This wo...

Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necros...
https://doi.org/10.1007/s12325-022-02173-7 10.1016/j.amjms.2017.12.014 10.1093/intimm/dxu102 10.7326/M16-0428 10.1111/apt.14997 10.1080/14712598.2017.1341486 10.1007/s40265-018-0881-y 10.1136/rmdopen-2018-000710 10.1007/s40259-018-0293-2 10.1371/journal.pone.0195012 10.1136/annrheumdis-2017-212820 10.1002/art.40402 10.14740/gr800w 10.1016/S0140-6736(17)30068-5 10.2147/DDDT.S130320 10.1111/jdv.14605 10.3390/jcm10153387 10.17235/reed.2020.6693/2019 10.1185/03007995.2016.1170673 10.1007/s12325-018-0742-9 10.5662/wjm.v2.i4.27 10.1080/14712598.2016.1198765 10.1016/j.semarthrit.2018.07.005 10.1136/annrheumdis-2017-eular.3672 10.1002/art.40444 10.1136/annrheumdis-2015-208783 10.1136/annrheumdis-2017-211741 10.1136/annrheumdis-2015-208786 10.1136/annrheumdis-2017-211591 10.1080/14712598.2017.1238454 10.1080/03007995.2019.1571296 10.1080/03007995.2018.1560221 10.1007/s12325-019-00998-3 10.1007/s12026-016-8843-5 10.1159/000453343 10.1371/journal.pone.0168005 10.1186/ar1881 10.1177/1060028016682330 10.1007/s40744-017-0078-y 10.1016/j.jbspin.2017.10.003 10.1007/s40258-018-0371-0 10.1136/gutjnl-2015-309290 10.1136/annrheumdis-2015-208684 10.1126/science.aan1221 10.1111/jgh.12997 10.1007/s10620-014-3392-z 10.1517/14712598.2015.1103733 10.1586/17474124.2015.1091309 10.2147/OARRR.S124975 10.1097/MEG.0000000000000953 10.1016/j.semarthrit.2017.10.002 10.1016/j.clinthera.2017.05.031 10.1093/ecco-jcc/jjx002.638 10.1016/j.gastrohep.2017.07.005 10.1136/ejhpharm-2017-000640.149 10.1093/rheumatology/kex062.055 10.1093/ecco-jcc/jjx002.555 10.1007/s10067-017-3686-6 10.1111/apt.14453 10.1093/ecco-jcc/jjx002.785 10.1007/s10620-017-4661-4 10.1093/ecco-jcc/jjx002.596 10.1136/annrheumdis-2017-eular.1128 10.1136/annrheumdis-2018-eular.5157 10.1093/ibd/izy264 10.1097/MEG.0000000000001113 10.1007/s00228-018-2418-4 10.1093/ecco-jcc/jjx180.715 10.1093/rheumatology/key075.465 10.1093/ecco-jcc/jjx180.734 10.1097/MPG.0000000000002091 10.17235/reed.2018.5368/2017 10.1136/annrheumdis-2018-eular.4716 10.1080/00365521.2018.1463391 10.1093/ibd/izx047 10.1136/annrheumdis-2018-eular.5750 10.1093/ecco-jcc/jjx180.655 10.1080/00365521.2018.1464203 10.1093/rheumatology/key075.456 10.1136/annrheumdis-2018-eular.2769 10.1002/art.40516 10.1002/art.40324 10.1136/annrheumdis-2018-eular.5844 10.1136/annrheumdis-2018-eular.3093 10.1093/rheumatology/key075.288
Advances in Therapy; Liu Y, Skup M et. al.

Jun 24th, 2022 - To examine the prevalence rates of biosimilar discontinuation and switchback to the originator tumor necrosis factor alpha (TNF) inhibitors following non-medical switch (NMS) in patients. Real-world studies reporting biosimilar discontinuation and...

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of N...
https://doi.org/10.3390/curroncol29060337
Current Oncology (Toronto, Ont.); Yang C, Khwaja R et. al.

Jun 24th, 2022 - The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we pre...

see more →

Guidelines  9 results

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0012
Journal of the National Comprehensive Cancer Network : JN... Benson AB, Venook AP et. al.

Mar 17th, 2021 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been mad...

Belgian IBD Research Group BIRD Position Statement 2019 on the Use of Adalimumab Biosim...
https://doi.org/10.1093/ecco-jcc/jjz209
Journal of Crohn's & Colitis; Somers M, Bossuyt P et. al.

Dec 27th, 2019 - The emergence of biosimilars is generally considered as an opportunity to guarantee accessibility to affordable treatments and to enhance financial sustainability of national health systems. Since 2017, five biosimilars of adalimumab were approved...

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the Am... Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Upd...
https://doi.org/10.1093/ecco-jcc/jjw198
Journal of Crohn's & Colitis; Danese S, Fiorino G et. al.

Dec 9th, 2016 - ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.|2016|Danese S,Fiorino G,Raine T,Ferrante M,Kemp K,|therapeutic use,standards,therapeutic use,drug therapy,therapeutic use,

see more →

Drugs  1 results see all →

Clinicaltrials.gov  27 results

Yuflyma® (Adalimumab), Patient Experience After Switching
https://clinicaltrials.gov/ct2/show/NCT05427942

Jun 22nd, 2022 - Patient preference and experience can impact patients' adherence and persistence regarding a treatment, especially when switching. A number of factors contribute to this, including their beliefs, fears, expectations, and overall knowledge. This is...

Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease
https://clinicaltrials.gov/ct2/show/NCT05424926

Jun 21st, 2022 - TNFα inhibitors have revolutionized the management of patients suffering from inflammatory diseases in the field of rheumatology. Infliximab remains widely used in France, and infliximab biosimilars have been routinely used since 2015 in Cochin Ho...

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
https://clinicaltrials.gov/ct2/show/NCT02626455

May 26th, 2022 - Patients should be in need of and fit for immunochemotherapy and should not be resistant to rituximab (resistance defined as lack of response or progression within 6 months of the last date of rituximab administration, including rituximab, and/or ...

Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
https://clinicaltrials.gov/ct2/show/NCT04841187

May 23rd, 2022 - PSOBIOTEQ is a national multicentric prospective non interventional study which aims to constitute a French registry of cutaneous psoriasis patients initiating systemic treatment (excluding acitretin and phototherapy) for moderate to severe cutane...

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
https://clinicaltrials.gov/ct2/show/NCT01903330

May 16th, 2022 - This is a blinded Phase II study of ERC1671 in combination with bevacizumab in patients with relapsed, bevacizumab naive glioblastoma. The patients who will be randomized (in a 1:1 ratio) to receive either ERC 1671 in combination with GM-CSF and c...

see more →

News  552 results

TNF Placental Transfer Makes Little Difference in Offspring Infections
https://www.medscape.com/viewarticle/975010

Jun 3rd, 2022 - COPENHAGEN — Here's reassuring news for pregnant women with rheumatic diseases treated with tumor necrosis factor alpha (TNFα) inhibitors: although the drugs vary widely in their transmissibility across the placenta, there appears to be no excess ...

Alleviating the Burden of Financial Toxicity Begins at the Point of Care
https://www.onclive.com/view/alleviating-the-burden-of-financial-toxicity-begins-at-the-point-of-care

Mar 29th, 2022 - Safety profiles of anticancer drugs represent only one piece of the toxicity puzzle patients grapple with following a cancer diagnosis. Financial toxicity, the unspoken burden, has come under the spotlight over the past 5 years as a topic that mor...

Insulin Biosimilars Expected in 2024; Dexcom's CGM for Hospital Use; Tymlos for Men?
https://www.medpagetoday.com/endocrinology/generalendocrinology/97506

Mar 6th, 2022 - The nonprofit drugmaker Civica announced plans to make three types of lower-cost insulin -- biosimilars of Lantus, Humalog, and Novolog -- which are expected to be available in the U.S. by 2024. (Reuters) The FDA granted breakthrough device design...

Biosimilars Offer Effective and Cost-Effective Alternatives to Biologics for Cancer Treatment
https://www.medscape.com/viewarticle/968666

Feb 17th, 2022 - NEW YORK (Reuters Health) - Biosimilar cancer drugs appear to be as safe and effective as the biologics they replace, and they cost much less, a systematic review and meta-analysis reports. "We found that for three widely-used cancer biologic drug...

Another Coffee Debate; Cancer Drugs and COVID; Breast Cancer Metabolic Risks
https://www.medpagetoday.com/hematologyoncology/othercancers/96766

Jan 20th, 2022 - The coffee debate continues: Women who drank more coffee, particularly caffeinated coffee, had a lower risk of endometrial cancer. (Journal of Obstetrics and Gynaecology Research) Tennis legend Chris Evert acknowledged that she has early-stage ova...

see more →